Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Luohu District Hospital of Traditional Chinese Medicine, ShenZhen, 518004, China.
Trials. 2022 Jan 31;23(1):94. doi: 10.1186/s13063-022-06020-6.
Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammatory response. Persistent allergic rhinitis (PAR) is a subtype of AR, but the treatment of PAR is still a problem. Acupuncture is used as an alternative therapy for AR in clinical practice. The aim of this study is to evaluate the effectiveness of acupuncture therapy combined with fluticasone propionate nasal spray in comparison to fluticasone propionate nasal spray alone in the relief of symptoms for PAR.
This study is a multicenter, single-blind, randomized controlled trial. A total of 260 eligible patients will be randomly assigned into the treatment group or the control group. The treatment group will receive the nasal fluticasone propionate combined with acupuncture, and the control group will receive fluticasone propionate nasal spray alone for 6 weeks. The primary outcome is the change in the Reflective Total Nasal Symptom Score (rTNSS) from baseline to the end of treatment, and the Total Non Nasal Symptom Score (TNNSS), reflective total ocular symptom score (rTOSS), Rhinitis Quality of Life Questionnaire (RQLQ), use of antiallergic drugs, and the Rhinitis Control Assessment Test (RCAT) are used as secondary outcomes. The participants will be followed up for another 24 weeks after treatment.
This clinical trial will be able to provide high level evidence on the acupuncture therapy combined with fluticasone propionate nasal spray in the treatment of PAR.
ISRCTN Registry, ID: ISRCTN44040506 . Registered on 22 July 2020.
变应性鼻炎(AR)是一种免疫球蛋白 E(IgE)介导的炎症反应。持续性变应性鼻炎(PAR)是 AR 的一种亚型,但 PAR 的治疗仍然是一个问题。在临床实践中,针灸被用作 AR 的替代疗法。本研究旨在评估与单独使用丙酸氟替卡松鼻喷雾剂相比,针灸联合丙酸氟替卡松鼻喷雾剂治疗 PAR 症状缓解的疗效。
这是一项多中心、单盲、随机对照试验。共有 260 名符合条件的患者将被随机分配到治疗组或对照组。治疗组将接受丙酸氟替卡松鼻喷雾剂联合针灸治疗,对照组仅接受丙酸氟替卡松鼻喷雾剂治疗 6 周。主要结局是从基线到治疗结束时反射性总鼻部症状评分(rTNSS)的变化,以及总非鼻部症状评分(TNNSS)、反射性总眼部症状评分(rTOSS)、鼻炎生活质量问卷(RQLQ)、抗过敏药物的使用以及鼻炎控制评估测试(RCAT)作为次要结局。治疗结束后,患者将再随访 24 周。
本临床试验将能够为针灸联合丙酸氟替卡松鼻喷雾剂治疗 PAR 提供高水平的证据。
ISRCTN 注册处,ID:ISRCTN44040506。于 2020 年 7 月 22 日注册。